Myriad Genetics Beats Q4 Expectations, Shares Surge Amid Core Franchise Growth

2026-02-24 10:10:32 ET

Thesis

Myriad Genetics, Inc. (MYGN) posted a pretty solid earnings beat for the fourth quarter of 2025, and the stock is up about 25% pre-market today. Non-GAAP EPS came in at $0.04, exceeding consensus expectations by $0.06, and revenue was $209.8 million, a figure that surpassed estimates by about $2.24 million; however, we did see a modest 0.4% year-over-year decline. Test volume growth was also quite strong, with decent performances in their franchises, which is what we wanted to see. This included Prolaris prostate cancer testing, up about 12%, and hereditary cancer testing, up about 9%. This was a much-needed boost to offset some pressure in other areas. Gross margin also remained pretty stable at 70.0%, which was in line with the prior quarter....

Read the full article on Seeking Alpha

For further details see: